BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 126700
Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Table 1 Molecular signatures of gastric cancer
Molecular
Behavior
Recurrence
Notes
MSIBest prognosisLow risk of recurrenceResistant to chemotherapy
PD-L1+Low risk of recurrenceSensitive to immunotherapy
MSS/EMT- (EBV+)Intermediate prognosisMiddle risk of recurrenceSensitive to chemo/immunotherapy
HER2+Intermediate prognosisMiddle risk of recurrenceSensitive to targeted therapy
MSS/EMT+Worst prognosisHigh risk of recurrence
Table 2 Definitions of oligometastatic disease
Consensus
Study
Appropriate candidates for conversion therapy
OMECKroese et al[50]Limited to 1 organ with ≤ 3 metastases, or involvement of 1 extra-regional lymph node station
KINGCAKim et al[54]Limited to 1 organ, or involvement of 1 extra-regional lymph node station or positive peritoneal cytology (Yoshida 1)
BertinoroMorgagni et al[52]≤ 3 resectable liver or lung metastases (excluded bones), or involvement of para-aortic nodes, or peritoneal cancer index ≤ 6


Write to the Help Desk